MannKind Corp (MNKD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.33B
Last updated: Nov 17, 2026 at 11:06 AM ET
MannKind Corp (MNKD) Earnings: Report Dates and Results
MannKind (MNKD) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, MannKind reported EPS of -$0.07, above the -$0.08 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
MNKD has an expected report date of Feb 24, 2027.
MNKD Earnings Call
The latest MNKD earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, MNKD beat 18, missed 18 and matched 4. Revenue for the quarter ended Sep 30, 2026 was $101.87M, up 24.0% from $82.13M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.07 | -$0.08 | N/A | +12.50% | Beat | -333.3% | 4 | 0 up, 1 down | Nov 5, 2026 | $101.87M |
| Jun 30, 2026 | -$0.06 | -$0.02 | N/A | -200.00% | Miss | -220.0% | 4 | N/A | Aug 5, 2026 | $109.37M |
| Mar 31, 2026 | -$0.02 | $0.01 | $0.00 - $0.02 | -398.51% | Miss | -150.0% | 3 | 0 up, 0 down | May 6, 2026 | $90.17M |
| Dec 31, 2025 | -$0.05 | -$0.01 | N/A | -400.00% | Miss | -266.7% | 3 | 0 up, 1 down | Feb 26, 2026 | $111.95M |
| Sep 30, 2025 | $0.03 | $0.01 | N/A | +200.00% | Beat | -25.0% | 3 | 0 up, 0 down | Nov 5, 2025 | $82.13M |
| Jun 30, 2025 | $0.05 | $0.08 | $0.06 - $0.10 | -37.50% | Miss | N/A | 3 | 0 up, 0 down | Aug 6, 2025 | $76.53M |
| Mar 31, 2025 | $0.04 | $0.06 | $0.06 - $0.06 | -33.33% | Miss | 0.0% | 1 | 0 up, 0 down | May 8, 2025 | $78.35M |
| Dec 31, 2024 | $0.03 | $0.04 | N/A | -25.00% | Miss | +597.7% | 2 | 0 up, 0 down | Feb 26, 2025 | $76.78M |
| Sep 30, 2024 | $0.04 | $0.03 | $0.02 - $0.04 | +33.33% | Beat | +300.0% | 3 | 1 up, 0 down | Nov 7, 2024 | $70.08M |
| Jun 30, 2024 | -$0.01 | $0.01 | $0.00 - $0.02 | -200.00% | Miss | N/A | 3 | 0 up, 0 down | Aug 7, 2024 | $72.39M |
| Mar 31, 2024 | $0.04 | $0.03 | $0.01 - $0.04 | +33.33% | Beat | N/A | 5 | 0 up, 0 down | May 8, 2024 | $66.26M |
| Dec 31, 2023 | $0.00 | $0.01 | -$0.02 - $0.04 | -57.00% | Miss | N/A | 6 | 1 up, 0 down | Feb 27, 2024 | $58.47M |
| Sep 30, 2023 | $0.01 | -$0.02 | -$0.03 - $0.00 | +150.00% | Beat | N/A | 6 | 0 up, 0 down | Nov 7, 2023 | $51.25M |
| Jun 30, 2023 | -$0.02 | -$0.04 | -$0.05 - -$0.02 | +50.00% | Beat | N/A | 5 | 0 up, 0 down | Aug 7, 2023 | $48.61M |
| Mar 31, 2023 | -$0.04 | -$0.05 | -$0.06 - -$0.04 | +20.00% | Beat | N/A | 5 | 0 up, 0 down | May 9, 2023 | $40.63M |
| Dec 31, 2022 | -$0.07 | -$0.06 | -$0.08 - -$0.05 | -16.67% | Miss | N/A | 5 | 1 up, 0 down | Feb 23, 2023 | $36.06M |
| Sep 30, 2022 | -$0.06 | -$0.08 | -$0.13 - -$0.03 | +25.00% | Beat | N/A | 5 | 0 up, 0 down | Nov 8, 2022 | $32.83M |
| Jun 30, 2022 | -$0.11 | -$0.09 | -$0.11 - -$0.08 | -22.22% | Miss | N/A | 5 | 0 up, 0 down | Aug 9, 2022 | $18.89M |
| Mar 31, 2022 | -$0.10 | -$0.10 | -$0.13 - -$0.08 | 0.00% | In line | N/A | 5 | 0 up, 0 down | May 5, 2022 | $11.99M |
| Dec 31, 2021 | -$0.11 | -$0.07 | -$0.10 - -$0.05 | -57.14% | Miss | N/A | 6 | N/A | Feb 24, 2022 | $12.52M |
| Sep 30, 2021 | -$0.04 | -$0.08 | -$0.08 - -$0.03 | +50.00% | Beat | N/A | 5 | 1 up, 0 down | Nov 9, 2021 | $22.21M |
| Jun 30, 2021 | -$0.05 | -$0.04 | -$0.05 - -$0.03 | -25.00% | Miss | N/A | 5 | N/A | Aug 11, 2021 | $23.28M |
| Mar 31, 2021 | -$0.05 | -$0.05 | -$0.05 - -$0.04 | 0.00% | In line | N/A | 4 | N/A | May 12, 2021 | $17.44M |
| Dec 31, 2020 | -$0.06 | -$0.04 | -$0.05 - -$0.03 | -50.00% | Miss | N/A | 5 | N/A | Feb 25, 2021 | $18.44M |
| Sep 30, 2020 | -$0.05 | -$0.05 | -$0.06 - -$0.04 | 0.00% | In line | N/A | 5 | N/A | Nov 4, 2020 | $15.35M |
| Jun 30, 2020 | -$0.05 | -$0.06 | -$0.06 - -$0.05 | +16.67% | Beat | N/A | 5 | N/A | Aug 5, 2020 | $15.11M |
| Mar 31, 2020 | -$0.04 | -$0.06 | -$0.07 - -$0.05 | +33.33% | Beat | N/A | 5 | N/A | May 6, 2020 | $16.23M |
| Dec 31, 2019 | -$0.07 | -$0.08 | -$0.09 - -$0.06 | +12.50% | Beat | N/A | 5 | N/A | Feb 25, 2020 | $15.99M |
| Sep 30, 2019 | -$0.07 | -$0.07 | -$0.09 - -$0.06 | 0.00% | In line | N/A | 5 | N/A | Nov 6, 2019 | $14.60M |
| Jun 30, 2019 | -$0.07 | -$0.08 | -$0.08 - -$0.06 | +12.50% | Beat | N/A | 4 | N/A | Aug 7, 2019 | $15.00M |
| Mar 31, 2019 | -$0.08 | -$0.13 | -$0.13 - -$0.07 | +38.46% | Beat | N/A | 2 | N/A | May 7, 2019 | $17.45M |
| Dec 31, 2018 | -$0.06 | $0.22 | -$0.17 - $1.00 | -127.27% | Miss | N/A | 3 | N/A | Feb 26, 2019 | $16.03M |
| Sep 30, 2018 | -$0.15 | -$0.18 | -$0.18 - -$0.18 | +16.67% | Beat | N/A | 1 | N/A | Nov 1, 2018 | $4.47M |
| Jun 30, 2018 | -$0.17 | -$0.20 | -$0.20 - -$0.20 | +15.00% | Beat | N/A | 1 | N/A | Aug 2, 2018 | $3.89M |
| Mar 31, 2018 | -$0.25 | -$0.23 | -$0.23 - -$0.23 | -8.70% | Miss | N/A | 1 | N/A | May 9, 2018 | $3.46M |
| Dec 31, 2017 | -$0.28 | -$0.29 | -$0.29 - -$0.29 | +3.45% | Beat | N/A | 1 | N/A | Feb 27, 2018 | $4.53M |
| Sep 30, 2017 | -$0.31 | -$0.20 | N/A | -55.00% | Miss | -123.8% | N/A | N/A | Nov 7, 2017 | $2.04M |
| Jun 30, 2017 | -$0.34 | -$0.23 | N/A | -47.83% | Miss | N/A | N/A | N/A | Aug 7, 2017 | $2.16M |
| Mar 31, 2017 | -$0.17 | $0.12 | N/A | -241.67% | Miss | N/A | N/A | N/A | May 10, 2017 | $3.01M |
| Dec 31, 2016 | -$0.19 | -$0.20 | N/A | +5.00% | Beat | N/A | N/A | N/A | Mar 16, 2017 | $12.40M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.07, within 4 cents of the year before. It was $0.46 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.07 | N/A |
| Dec 31, 2024 | $0.10 | N/A |
| Dec 31, 2023 | -$0.05 | N/A |
| Dec 31, 2022 | -$0.34 | N/A |
| Dec 31, 2021 | -$0.25 | N/A |
| Dec 31, 2020 | -$0.20 | N/A |
| Dec 31, 2019 | -$0.29 | N/A |
| Dec 31, 2018 | -$0.63 | N/A |
| Dec 31, 2017 | -$1.10 | -339.1% |
| Dec 31, 2016 | $0.46 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,300 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,288 | 10 | |
| 2026Q2 | Jun 30, 2026 | 8,605 | 11 | |
| 2026Q1 | Mar 31, 2026 | 7,456 | 10 | |
| 2025Q4 | Dec 31, 2025 | 5,940 | 7 | |
| 2025Q3 | Sep 30, 2025 | 6,627 | 9 | |
| 2025Q2 | Jun 30, 2025 | 6,050 | 10 | |
| 2025Q1 | Mar 31, 2025 | 5,463 | 9 | |
| 2024Q4 | Dec 31, 2024 | 6,791 | 9 |
2026Q3 Earnings Call
Opening remarks
Michael Castagna Chief Executive Officer Thank you, operator, and good afternoon, everyone. Thank you for joining us for our third quarter 2026 earnings call. I'll start with our quarter highlights, then provide some business updates, while Chris walks us through our financial results, and I'll provide some closing remarks. Last quarter, I told you we had delivered all three catalysts we laid out for 2026. This quarter is about what comes next: moving from delivering catalysts to executing against them. Before we get into the quarter, I want to take a step back and look at how far MannKind has come. Five years ago, we were a company with roughly $75 million in revenue and one commercial product. Since then, we've grown revenue at a compound annual rate of more than 40%. And this year, we expect to be close to six times that size. What I'm most proud of is how we've grown. We didn't get there on a single product or a single deal. First, our collaboration with United Therapeutics took off, and Tyvaso DPI became a blockbuster built on our DPI technology. Its royalties and manufacturing revenue have funded our transformation. We used this foundation to expand our commercial business, and today, Furoscix and Afrezza are leading our growth. That growth is now reaching the bottom line. We expect record revenue in Q4 to drive us to profitability as we close out the year. And none of this reflects our pipeline or external business development opportunities that can drive faster inorganic growth. So today, MannKind isn't a single-product story anymore. We're a diversified growth company with four FDA-approved products, no near-term IP cliffs, and no concentrated risk on any one brand or therapeutic area. Today, we have three value engines driving growth. Each one plays a different role. First, we hit the key milestones laid out this year, and our commercial launches are growing nicely. Furoscix ReadyFlow is off to an exceptional start, with rapid conversion from the On-body Infuser and new patient growth. And the Afrezza pediatric launch is seeing strong early adoption. Second, our license agreement with United Therapeutics provides MannKind with cash flow that funds development and will start to drop to the bottom line in 2027 and beyond. We anticipate $15 million in milestones from ralinepag DPI in 2027. Third, our DPI platform provides upside. This is long-term value creation. Nintedanib DPI is our lung-targeted approach to IPF treatment, and key clinical evidence investors should look for is the data readout we're anticipating in the first half of 2028. And with our out-licensed programs, Tyvaso DPI and ralinepag DPI give us three potential paths in IPF. Now let me hit the exciting highlights for the quarter.
Frequently Asked Questions About MNKD
When is MannKind's next earnings date?
MannKind's next earnings report is expected for Feb 24, 2027.
Did MNKD beat earnings estimates last quarter?
Yes. MannKind reported EPS of -$0.07 for the quarter ended Sep 30, 2026, above the -$0.08 estimate, a 12.50% surprise.
What EPS do analysts expect from MNKD next quarter?
The consensus EPS estimate for MannKind for the quarter ending Dec 31, 2026 is $0.00 from 11 analysts, with estimates from -$0.06 to $0.04.
How often does MNKD beat earnings estimates?
MannKind beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -110.23%.
MNKD pages: Overview, Earnings, Forecast, Financials, Competitors